Adagrasib

(Krazati®)

Adagrasib

Latest News

loading GIF

Drug updated on 4/18/2024

Dosage FormTablet (oral; 200 mg)
Drug ClassRAS GTPase family inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Adagrasib (Krazati) is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy.
  • Two studies were reviewed, focusing on the efficacy and safety of adagrasib in treating KRAS^G12C-mutated solid tumors, including non-small cell lung cancer.
  • The objective response rate (ORR) was reported as 31% in a study that included 18 studies with 1224 patients. However, another study focused specifically on NSCLC showed an ORR of 37%, suggesting potential heightened efficacy within lung cancer populations.
  • There is a notable difference in the incidence of grade ≥3 adverse events between different types of solid tumors being treated; it's lower for broader analysis (29%) compared to an NSCLC-specific study (44%), indicating that the safety profile might vary significantly depending upon the patient population and type of tumor.
  • Patients with KEAP1 co-mutation may not benefit as significantly from these treatments due to inferior response rates. This underscores the significance of personalized treatment approaches within this domain.
  • Compared to other KRAS^G12C inhibitors, adagrasib demonstrates considerable efficacy and manageable safety profile consistent with collective data presented for this class but direct comparisons are limited by available data.

Product Monograph / Prescribing Information

Document TitleYearSource
Krazati (adagrasib) Prescribing Information.2022Mirati Therapeutics, Inc. 3545 Cray Court San Diego, CA

Systematic Reviews / Meta-Analyses